Emergent BioSolutions [EBS] Downgraded to Equal-Weight at Wells Fargo
Wells Fargo took its Emergent BioSolutions [EBS] rating to the equivalent of Equal-Weight from Overweight, in a research note dated 2021-01-08. Meanwhile, Chardan Capital Markets had maintained its rating on EBS to the earlier “Buy” rating, in a research note produced for clients July 31, 2020. In addition, Guggenheim launched coverage on September 12, 2019. […]
